Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 15th. The shares were sold at an average price of $31.32, for a total transaction of $469,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Harmony Biosciences stock opened at $31.50 on Thursday. Harmony Biosciences Holdings, Inc. has a 52-week low of $25.46 and a 52-week high of $52.74. The business has a 50 day moving average price of $29.89. The company has a quick ratio of 5.18, a current ratio of 5.32 and a debt-to-equity ratio of 1.81. The stock has a market capitalization of $1.79 billion and a P/E ratio of 150.00.
Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Monday, May 10th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.41. As a group, analysts predict that Harmony Biosciences Holdings, Inc. will post 0.97 EPS for the current year.
Hedge funds have recently added to or reduced their stakes in the business. New York State Common Retirement Fund acquired a new stake in Harmony Biosciences during the fourth quarter worth approximately $127,000. Citigroup Inc. acquired a new stake in Harmony Biosciences during the fourth quarter worth approximately $48,000. Jefferies Group LLC acquired a new stake in Harmony Biosciences during the fourth quarter worth approximately $368,000. Janus Henderson Group PLC raised its holdings in Harmony Biosciences by 25.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,094,449 shares of the company’s stock worth $39,562,000 after purchasing an additional 219,540 shares in the last quarter. Finally, Ashford Capital Management Inc. acquired a new stake in Harmony Biosciences during the fourth quarter worth approximately $9,867,000. 48.28% of the stock is currently owned by institutional investors.
Several research analysts have recently commented on the stock. The Goldman Sachs Group raised shares of Harmony Biosciences from a “neutral” rating to a “buy” rating and raised their price objective for the company from $41.00 to $43.00 in a research note on Monday, March 29th. Zacks Investment Research raised shares of Harmony Biosciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 25th.
Harmony Biosciences Company Profile
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States.
Recommended Story: What are municipal bonds?